Knowledgeable physicians can easily diagnose PSP when the disease presents with its classical features, but at early disease stages or when it presents with atypical features, the hunted biologic markers are expected to be of assistance. Palliative treatment rather than neurotransmitter replacement therapies are being used in clinical practice, whereas coordinated research efforts to find the cause and cure for this devastating disease remain crucial (Box). It is conceivable that therapeutic strategies aimed at limiting free radical production, oxidative stress, inflammation, and/or tau aggregation, may slow the advance of PSP. The availability of recently developed four-repeat tau-animal models resembling PSP will likely accelerate the translation of research from bench to bedside. It is hoped that as a result of these efforts, investigators will identify biologic markers to diagnose PSP at earlier stages and will develop biologic therapies that could prevent the abnormal aggregation of tau and prolong neuronal survival, which in turn will slow or stop the disease progression.
Was this article helpful?